|
Original
Articles
仜Lipid-mediated presentation of MHC class II molecules guides thymocytes
to the CD4 lineage.丂Komaniwa S., Hayashi H., Kawamoto H., Sato S.B., Ikawa T., Katsura Y.
and Udaka K.丂Eur J Immunol 39,1亅7, 2009.
仜Biochemical visualization of
cell surface molecular clustering in living cells.丂Kotani N., Gu J., Isaji T., Udaka K., Taniguchi N. and Honke K.丂Proc Natl Acad Sci USA 105(21),
7405-7409, 2008.
仜丂Human
leukocyte antigen-G, a ligand for the natural killer receptor KIR2DL4, is
expressed by eutopic endometrium only in the menstrual phase.丂Kawashima M., Maeda N.,
Adachi Y., Takeuchi T., Yamamoto Y., Izumiya C., Hayashi K., Furihata M., Udaka
K. and Fukaya T.丂Fertil Steril, 2008 [Epub
ahead of print]
仜Wilms乫 tumor 1 gene expression is increased in hepatocellular carcinoma
and associated with poor prognosis.丂Sera T., Hiasa Y., Mashiba T., Tokumoto Y., Hirooka M., Konishi I., Matsuura
B., Michitaka K., Udaka K. and Onji M.丂Eur J Cancer, 44(4),600-608,
2008.
仜 Wilms乫 tumor gene WT1
peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.丂Tsuboi A., Oka Y., Nakajima H., ukuda Y., Elisseeva O.A., Yoshihara S.,
Hosen N., Ogata A., Kito K., Fujiki F., Nishida S., Shirakata T., Ohno
S., Yasukawa M., Oji Y., Kawakami M., Morita S., Sakamoto J., Udaka K.,
Kawase I. and Sugiyama H.丂Int J Hematol 86(5),
414-417, 2007.
仜 Potent CTL induction by a whole cell pertussis vaccine in anti-tumor
peptide immunotherapy. Yano A., Komatsu T. Ishibashi M. and Udaka K. Microbiology
and Immunology 51(7) , 685-699, 2007.
仜 WT1 (Wilms' Tumor 1) peputide immunotherapy for renal cell carcinoma.
Iiyama T., Takeda S., Udaka K., Takeuchi T., Adachi Y.C., Shuin T., Ohtsuki
Y., Oka Y., Tsuboi A., Nakatsuka S., Elisseeva O.A., Oji Y., Nakajima H.,
Kawakami M., Nishida S., Shirakata T., and Sugiyama H. Microbiology and
Immunology 51(5), 59-530, 2007.
仜 Identification and characterization of a WT1(Wilms' tumor gene) protein-derived
HLA-DR1 *0405-restricted 16-mer helper peptide that prmotes the induction
and activation of WT1-Specific cytoxic T lymphocytes. Fujiki F., Oka Y.,
Tsuboi A., Kawakami M.., Kawakatsu M., Nakajima H., Elisseeva O.A., Harada
Y., Ito K., Li Z., Tatsumi N., Sakaguchi N., Fujioka T., Masuda T., Yasukawa
M., Udaka K., Kawase I., Oji Y. and Sugiyama H. Journal of Immunotherapy
30(3), 282-293, 2007.
仜 Identification of CTL epitopes in hepatitis C virus by a genome-wide
computational acanning and a rational design of peptide vaccine. Mashiba
T., Udaka K., Hirachi Y., Miyakawa T., Satta Y., Osada T., Kataoka S.,
Kohara M. and Onji M. Immunogenetics 59, 197-209, 2007.
仜 Structure of the cadherin-rerated neuronal receptor/protocadherin-兛 first
cadherin domain reveals diversity across cadherin families. Morishita H.,
Umitsu M., Murata Y., Shibata N., Udaka K., Higuchi Y., Akutsu H., Yamaguchi
T. and Ikegami T. J. Biol. Chem 281(44), 33650-33663, 2006.
仜丂A phase I/II trial of a WT1(Wilms' Tumor Gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Morita S., Oka Y., Tsuboi A., Kawakami M., Maruno M., Izumoto S., Osaki T., Taguchi T., Ueda T., Myoui A., Nishida S., Shirakawa T., Ohno S., Oji Y., Aozasa K., Hatazawa J., Udaka K., Yoshikawa H., Yoshimine T., Noguchi S., Kawase I., Nakatsuka S., Sugiyama H. and Sakamoto J. Jpn. J. Clin. Oncol. 36(4), 231-236, 2006.
仜 Improving MHC binding peptide prediction by incorporating binding data
of auxiliary MHC molecules. Zhu S., Udaka K., Sidney J., Sette A., Aoki-Kinoshita
K.F. and Mamitsuka H. Bioinfomatics 22(13), 1648-1655, 2006.
仜WT235 , a ninemer peptide derived from Wilms' tumor
gene product, is a candidate peptide for the vaccination of
HLA-A*0201-positive patients with hematopoietic malignancies. Li Z., Oka
Y., Tsuboi A., Masuda T., Tatsumi N., Kawakami M., Fujioka T., Sakaguchi
N., Nakajima H., Fujiki F., Udaka K., Oji Y., Kawase I. and Sugiyama H.
Int. J. Hematol. 82, 458-459, 2005.
仜Fyn regulated eosinophil
infiltration into the conjunctiva by downregulating the Th2 response. A. Fukushima, T. Yamaguchi, A.
Ozaki, T. Taniguchi, K. Udaka and H. Ueno Grafes Arch. Clin. Exp.
Ophthalmol. 243, 1043-1049, 2005.
仜 Mice lacking the IFN-gamma receptor or fyn develop severe experimental autoimmune uveoretinitis characterized by different immune
responses. A. Fukushima, T. Yamaguchi, W. Ishida, K. Fukata, K. Udaka and H.
Ueno Immunogenetics
57(5),337-343, 2005.
仜 1H, 13C and 15N resonance assignments of the first cadherin domain of Cadherin-related neuronal receptor CNR)/ protocadherin alpha. M. Umitsu, H. Morishita, Y.
Murata, K. Udaka, H. Akutsu, T. Yagi and T. Ikegami J.
Biomol. NMR. 31(4),365-366,2005.
仜 Induction of WT1(Wilms乫 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the
resultant cancer regression. Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. kyo, H. Nakajima, O.A.Elisseeva, Y. Oji, M. Kawakami, K. Ikegami, N.
Hosen, S. Yoshihara, F. Wu,
F. Fujiki, M. Murakami, T. Masuda, S. Nishida,
T. Shirakawa, S. Nakatsuka, A. Sasaki, K. Udaka, H. Dohy, K. Aozasa, S. Noguchi, I. Kawase and H. Sugiyama Proc. Natl. Acad. Sci USA, 21, 13885-13890, 2004.
仜 WT1 peptide-based immunotherapy for patients with lung cancer: Report
of two case. A. Tsuboi, Y. Oka, T. Osaki, T.
Kumagai, I. Tachibana, S. Hayashi, M. Murakami,
H. Nakajima, O.A. Elisseeva, W. Fei, T. Masuda, M. Yasukawa, Y. Oji, M. Kawakami, N.
Hosen, K. Ikegame, S. Yoshihara, K. Udaka, S.-I. Nakatsuka, K. Aozasa, I. Kawase and H. Sugiyama.
Microbiol. Immunol.
48, 175-184,
2004.
仜 Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt
Leukemia from Myelodysplastic Syndrome (MDS) or MDA with Myelofibrosis.
Y. Oka, A. Tsuboi, M. Murakami, M. Hirai, N. Tominaga, H. Nakajima, O.A.
Elisseeva, T. Yasukawa, H. Ogawa, I. Kawase and H. Sugiyama.
Int. J. Hematology 78,56-61, 2003.
仜 Actin-rich spherical extrusion induced in Okadaic acid-treated K562 cells
by crosslinking of membrane microdomains. T. Baba, K. Udaka, N. Terada,
H. Ueda, Y. Fujii, S. Ohno and S.B. Sato J. Histochem. Cytochem.
51, 1-8, 2003.
仜 Enhanced induction of human WT1-specific cytotoxic T lymphocytes with
a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. A. Tsuboi,
Y. Oka, K. Udaka, M. Murakami, T. Masuda, A. Nakano, H. Nakajima, M. Yasukawa,
A. Hiraki, Y. Oji, M. Kawakami, N. Hosen, T. Fujioka, F. Wu, Y. Taguchi,
S. Nishida, M. Asada, H. Ogawa, I. Kawase and H. Sugiyama Cancer
Immunol. Immunother.51(11-12), 614-620, 2002.
仜 Empirical evaluation of a dynamic experiment design method for prediction
of MHC class I-binding peptides.Keiko Udaka, Hiroshi Mamitsuka, Yukinobu
Nakaseko and Naoki Abe. J Immunol, 169, 5744-5753, 2002.
仜 Humoral immune responses against Wilms乫 tumor gene WT1 product in patients
with hematopoietic malignancies. O. A Elisseeva, Y. Oka, A. Tsuboi K. Ogata,
F. Wu, E.H. Kim, T. Soma H. Tamaki, M. Kawakami, Y. Oji, N. Hosen, T. Kubota
M. Nakagawa, T. Yamagami, A. Hiraoka, M. Tsukaguchi, K. Udaka, H. Ogawa,
T. Kishimoto, T. Nomura and H. Sugiyama Blood 99, 3272-3279, 2002.
仜 NMR study on the interaction between MHC class I protein and its antigen
peptide. Masatoshi Nakagawa, Kaori Chiba-Kamoshida, Keiko Udaka and Hiroshi
Nakanishi. Biochem Biophys Res Commun 278, 609-613, 2000.
仜 An automated prediction of MHC class I-binding peptides based on positional
scanning with peptide libraries. K. Udaka, K.-H. Wiesmuller, S. Kienle,
G. Jung, H. Tamamura, H. Yamagishi, K. Okumura, P. Walden, T. Suto and
T. Kawasaki. Immunogenetics, 51(10), 816-828, 2000.
仜 Cytotoxic T-lymphocyte responses elicited to Wilms乫 tumor gene WT1 product
by DNA vaccination. A. Tsuboi, Y. Oka, H. Ogawa, O.A. Elisseeva, H. Li,
K. Kawasaki, K. Aozasa, T. Kishimoto, K. Udaka, and H. Sugiyama J.
Clin. Immunol. 20(3), 195-202, 2000.
仜 Efficient induction of peptide specific cytotoxic T lymphocytes by LPS
activated spleen cells. Kiyokazu Kakugawa, Keiko Udaka, Kosuke Nakashima,
Kayo Inaba, Yoshihiro Oka, Haruo Sugiyama, Hirokazu Tamamura, Hideo Yamagishi.
Microbiol. Immunol. 44, 123-133, 2000.
仜 Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Keiko Udaka,
Yoshihiro Oka, Akihiro Tsuboi, Olga Elisseeva, Hiroyasu Ogawa, Katsuyuki
Aozasa, Tadamitsu Kishimoto and Haruo Sugiyama. J. Immunol. 164, 1873-1880,
2000.
仜 Human cytotoxic T cell response specific for peptides of wild-type Wilms乫
tumor gene (WT1) product. Y. Oka, O.A. Elisseeva, A. Tsuboi, H. Ogawa,
H. Tamaki, H. Li, Y. Oji, E.H. Kim, T. Soma, M. Asada, K. Ueda, E. Maruya,
H. Saji, T. Kishimoto, K. Udaka and H. Sugiyama Immunogenetics, 51, 99-107,
2000.
仜 Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient
mice : Implication for gene therapy. Y. Ohtsuka, K. Udaka, Y. Yamashiro,
H. Yagita and K. Okumura. J. Immunol. 160, 4635-4640, 1998.
仜 Impaired induction of cytotoxic T lymphocytes by antagonism of a weak
agonist borne by a variant hepatitis C virus epitope. Takashi Kaneko, Takashi
Moriyama, Keiko Udaka, KazumasaHiroishi, Hiroto Kita, Hiroaki Okamoto,
Hideo Yagita, Ko Okumura and MichioImawari.Eur. J. Immunol.丂27, 1782-1787,
1997.
仜 Self MHC-restricted peptides recognized by an alloreactive T lymphocyte
clone.KeikoUdaka, Karl-Heinz Wiesmuller, Stefan Kienle, Gunther Jung and
Peter Walden. J. Immunol. 157, 670-678, 1996
仜 Tolerance to amino acid variations in peptides binding to the MHC class
I proetin H-2Kb.Keiko Udaka, Karl-Heinz Wiesmuller, Stefan Kienle, Gunther
Jung and Peter Walden.J. Biol. Chem. 270, 24130-24134, 1995
仜 Decrypting the structure of MHC-I restricted CTL epitopes with complex
peptide libraries. Keiko Udaka, Karl-Heinz Wiesmuller, Stefan Kienle, Gunther
Jung and Peter Walden. J. Exp. Med. 181, 2097-2108. 1995.
仜 CD4, CD8 T cells and T cells are responsible for cytotoxicity raised in 2-microglobulin deficient mice against cells having normal MHC
class I expression.KeikoUdaka, SuzanaMarusic-Galesic, Peter Walden.J. Immunol. 153 : 2843 - 2850, 1994.
仜 A ubiquitous protein is the source of naturally occurring peptides that are recognized by a CD8+ T cell clone.KeikoUdaka, Theodore J. Tsomides,
Peter Walden, Naomi Fukusen and Herman. N. Eisen. Proc. Natl. Acad. Sci. USA 90, 11272-11276, 1993.
仜 A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I
MHC protein. Keiko Udaka, Theodore J. Tsomides, Herman N. Eisen.Cell. 69, 989-998, 1992.
Review
Articles
仜 Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Oka Y., Tsuboi A., Kawakami M., Ellisseeva O.A., Nakajima H., Udaka K., Kawase I., Oji Y. and Sugiyama H. Current medicinal Chemistry 3, 2345-2352, 2006.
仜 Cellular and humoral immune responses against Wilms' tumor gene WT1 product
(WT1) which overexpresses in various kinds of malignant neoplasms --- Toward
the development of cancer vaccine targeting WT1 ---. Oka Y. Tsuboi A.,
Elisseeva O,A., Oji Y., Udaka K. and Sugiyama H. Recent Res. Devel. Immunology
5, 97-114, 2003.
仜 WT1 as a novel target antigen for cancer immunotherapy. Oka Y., Tsuboi
A., Elisseeva O.A., Udaka K. and Sugiyama H. Current Cancer Drug Targets
2, 45-54, 2002.
仜 Decrypting class I MHC-bound peptides with peptide libraries. K. Udaka.
TiBS (Trends in Biochemical Sciences
) 21, 7-11, 1996.
|
